WAT
NYSEWaters Corporation
News · 26 weeks50+200%
2026-03-012026-08-23
Mix2390d
- Other8(35%)
- Analyst5(22%)
- SEC Filings4(17%)
- Insider4(17%)
- Earnings2(9%)
Latest news
25 items- SECSEC Form 8-K filed by Waters Corporation8-K - WATERS CORP /DE/ (0001000697) (Filer)
- SECSEC Form 10-Q filed by Waters Corporation10-Q - WATERS CORP /DE/ (0001000697) (Filer)
- INSIDERDirector Kuebler Christopher A sold $1,442,930 worth of shares (3,626 units at $397.94) and exercised 3,626 shares at a strike of $136.43 (SEC Form 4)4 - WATERS CORP /DE/ (0001000697) (Issuer)
- ANALYSTWaters upgraded by TD Cowen with a new price targetTD Cowen upgraded Waters from Hold to Buy and set a new price target of $475.00
- SECWaters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition8-K - WATERS CORP /DE/ (0001000697) (Filer)
- PRWaters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial ResultsSecond Quarter 2026 HighlightsTotal reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew 4%
- PRWaters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass SpectrometerBrings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology.Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volumes, introducing a step-change in analytical performance for complex biological matrices.Up to six-fold increase in robustness with StepWave™ XR Ion Guide vs. Xevo TQ Absolute MS, advancing laboratory productivity and performance consistency.MILFORD, Mass., July 27, 2026 /CNW/ -- The Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting — Waters Corporation (NYSE:WAT) today announced the l
- ANALYSTRBC Capital Mkts initiated coverage on Waters with a new price targetRBC Capital Mkts initiated coverage of Waters with a rating of Outperform and set a new price target of $435.00
- INSIDERDirector Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)4 - WATERS CORP /DE/ (0001000697) (Issuer)
- INSIDERDirector Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)4 - WATERS CORP /DE/ (0001000697) (Issuer)
- PRWaters Corporation Schedules Second Quarter 2026 Earnings Conference CallMILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least September 1, 2026, at midnight Eastern Time. About Waters CorporationWaters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, o
- ANALYSTBernstein resumed coverage on Waters with a new price targetBernstein resumed coverage of Waters with a rating of Outperform and set a new price target of $435.00
- INSIDERSVP Waters Analytical Sciences Carpio Robert L Iii covered exercise/tax liability with 189 shares, decreasing direct ownership by 5% to 3,426 units (SEC Form 4) (for withholding tax)4 - WATERS CORP /DE/ (0001000697) (Issuer)
- SECSEC Form 11-K filed by Waters Corporation11-K - WATERS CORP /DE/ (0001000697) (Filer)
- PRIMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision MedicineIMU’s AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time.Waters Biosciences’ technologies, including BD FACSDiscover™ and BD Rhapsody™ Instruments, will be used with IMU’s AI analytics in research to deliver deeper, population-level disease insights.Partnership supports IMU’s expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling.IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, and Waters Corporation (NYSE:WAT) today anno
- ANALYSTPiper Sandler initiated coverage on Waters with a new price targetPiper Sandler initiated coverage of Waters with a rating of Neutral and set a new price target of $400.00
- PRWaters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical AnalysisIntegrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway.Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%.Industry-leading Coin Cell DSC temperature range from –80 °C to 600 °C, aiding battery development and QA/QC.MILFORD, Mass., June 9, 2026 /CNW/ -- Waters Corporation (NYSE:WAT) today announced the launch of the Waters TA Instruments™ Coin Cell Differential Scanning Calorimeter (DSC), designed to transform battery safety testing. Purpose-built for battery scientists, the Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-intensive prepa
- PRWaters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component AnalysisFaster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness.Industry-first chemical and physical particle optimization delivers reproducible methods for increasingly complex biologics.MILFORD, Mass., June 8, 2026 /CNW/ -- 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-o
- PRWaters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection DiagnosticsFDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics.Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.Fully automated solution delivers an industry-leading 50% increase in vial loading and up to 960-vial per module capacity, maximizing walk-away time.MILFORD, Mass., June 3, 2026 /CNW/ -- Waters Corporation (NYSE:WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in
- ANALYSTWolfe Research resumed coverage on Waters with a new price targetWolfe Research resumed coverage of Waters with a rating of Outperform and set a new price target of $425.00
- PRWaters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics ResearchDelivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows.Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.Sets a new benchmark for throughput in high-resolution spatial analysis with the DESI XS source, supporting higher-confidence studies of disease and treatment response.MILFORD, Mass., June 1, 2026 /CNW/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics—Waters Corporation (NYSE:WAT) today introduced the Waters Xevo™
- PRWaters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals.50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.Integrated MALDI XS and DESI XS imaging with high-resolution ion mobility enables direct visualization of molecules in tissue, improving understanding of how disease develops at the cellular level.MILFORD, Mass., June 1, 2026 /PRNewswire/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics— Waters Corporation (NYSE:WAT) today announced the launch of
- SECSEC Form SD filed by Waters CorporationSD - WATERS CORP /DE/ (0001000697) (Filer)
- SECSEC Form 8-K filed by Waters Corporation8-K - WATERS CORP /DE/ (0001000697) (Filer)
- PRWaters Corporation to Present at the Jefferies Global Healthcare ConferenceMILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, 2026, at 10:30 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days.About Waters CorporationWaters Corporation (NYSE:WAT) is a global leader in life sciences, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and se
WAT FAQ
7 questionsWhat does Waters Corporation do?
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based...Where does WAT stock trade?
Waters Corporation (WAT) is listed on NYSE.What sector and industry is WAT in?
Waters Corporation operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Waters Corporation go public?
Waters Corporation (WAT) completed its IPO in 1995.What are analysts saying about WAT?
Waters Corporation has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-08-05.What companies are similar to WAT?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), A (Agilent Technologies Inc.), PKI (PerkinElmer Inc.). Compare WAT side-by-side with any of them on Quantisnow.How can I track WAT on Quantisnow?
Quantisnow aggregates Waters Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WAT to receive live email and push alerts on every new disclosure.